A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03246529 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 11, 2017
Last Update Posted : June 16, 2022
|
Sponsor:
BioLineRx, Ltd.
Information provided by (Responsible Party):
BioLineRx, Ltd.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
A total of 207 subjects will be randomized into the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Multiple Myeloma | Drug: BL-8040 1.25mg/kg + G-CSF Drug: Placebo +G-CSF | Phase 3 |
- Part 1: This lead-in period designed to ascertain the dose of BL-8040 will enroll a total of up to 30 subjects to an open labeled treatment to assess the efficacy, safety, PK and PD parameters of treatment with G-CSF 10 µg/kg/day and BL-8040 1.25mg/kg, per study protocol to goal collection of ≥ 6x106 CD34+ cells/kg.
- Part 2: Following the successful completion of Part 1, a total of 177 subjects will be randomized into Part 2 of the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 136 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | subjects will be randomized using a 2:1 ratio to receive G-CSF + BL-8040 or G-CSF + Placebo, respectively. Randomization will use permuted blocks stratifying subjects by US geographical region (NorthEast, SouthEast, MidWest, SouthWest and NorthWest), remission status (CR vs. PR), and baseline platelet count (< 200 X 109/L or ≥ 200 X 109/L). |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma - The GENESIS Study |
| Actual Study Start Date : | March 23, 2018 |
| Actual Primary Completion Date : | December 22, 2020 |
| Estimated Study Completion Date : | December 22, 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Multiple myeloma
MedlinePlus related topics:
Multiple Myeloma
| Arm | Intervention/treatment |
|---|---|
|
Experimental: BL-8040 1.25mg/kg + G-CSF
double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
|
Drug: BL-8040 1.25mg/kg + G-CSF
Up to 2 SC injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care |
|
Active Comparator: Placebo + G-CSF
double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
|
Drug: Placebo +G-CSF
Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care |
Primary Outcome Measures :
- Proportion of subjects mobilizing ≥6.0 x 106 CD34+ cells/kg with up to 2 apheresis sessions [ Time Frame: 18 months ]Proportion of subjects mobilizing ≥6.0 x 106 CD34+ cells/kg with up to 2 apheresis sessions in preparation for auto-HCT after treatment with G-CSF + single administration of BL-8040 or G-CSF + placebo.
Secondary Outcome Measures :
- Proportion of subjects who collect ≥2.0 x 106 CD34+ cells/kg in 1 apheresis session [ Time Frame: 18 months ]Proportion of subjects who collect ≥2.0 x 106 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040 or G-CSF + placebo.
- Proportion of subjects who collect ≥6.0 x 106 CD34+ cells/kg in 1 apheresis session [ Time Frame: 18 months ]Proportion of subjects who collect ≥6.0 x 106 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040 or G-CSF + placebo.
- Time to neutrophil engraftment, after autologous hematopoietic cell transplantation [ Time Frame: 18 months ]Time to neutrophil engraftment, after autologous hematopoietic cell transplantation, as defined as ANC ≥0.5 x 109/L for 3 days or ≥1.0 x 109/L for 1 day following the conditioning regimen associated nadir.
- Time to platelet engraftment, after autologous hematopoietic cell transplantation [ Time Frame: 18 months ]Time to platelet engraftment, after autologous hematopoietic cell transplantation, as defined as the first of 3 consecutive measurements of platelet count ≥20 x 109/L without platelet transfusion support for 7 days following the conditioning regimen associated nadir.
- Graft durability at 100 days post engraftment. [ Time Frame: 18 months ]Graft durability at 100 days post engraftment, after autologous hematopoietic cell transplantation.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 78 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically confirmed Multiple Myeloma prior to enrolment and randomization.
- At least 1 weeks (7 days) from last induction cycle of combination/multi-agent cyto-reductive chemotherapy and no single agent chemotherapy/maintenance within 7 days (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc).
- Eligible for Autologous Hematopoietic stem cell transplantation according at the investigator discretion.
- The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Adequate organ function at screening .
- Subjects must use effective contraception.
Exclusion Criteria:
- Previous history of autologous or allogeneic-HCT
- Failed previous HSC collections or collection attempts.
- Patients whose apheresis product were to be further selected and purified
-
Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
- Dexamethasone: 7 days
- Thalidomide: 7 days
- Lenalidomide: 7 days
- Pamolidomide: 7 days
- Bortezomib: 7 days
- Carfilzomib: 7 days
- G-CSF: 14 days
- GM-CSF or Neulasta®: 21 days
- Combination/multi-agent cyto-reductive therapy
- Erythropoietin or erythrocyte stimulating agents: 30 days
- Eltrombopag, romiplostim or platelet stimulating agents: 30 days
- Carmustine (BCNU): 42 days/6 weeks
l. Daratumumab: 28 days m. Ixazomib: 7 days
- Received >6 cycles lifetime exposure to Lenalidomide.
- Received >8 cycles of alkylating agent combinations.
- Received > 6 cycles of melphalan
- Received 3-bis(2-chloroethyl)-1nitrl.
- Received prior treatment with radioimmunotherapy, (e.g. radionuclides, holmium).
-
Received marrow stimulating factors:
- Received G-CSF within 14 days prior to anticipated first dose of G-CSF.
- Received Pegfilgrastim (GM-CSF or Nulesta) within 3 weeks prior to anticipated first dose of G-CSF.
- Received erythrocyte of platelet stimulating agents within 30 days prior to anticipated first dose of G-CSF
- Plans to receive maintenance treatment within 60 days post-engraftment (e.g. Lenalidomide, Bortezomib, Pomalidomide, Thalidomide, Carfilzomib, etc.)
- Has received a live vaccine within 30 days of the planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
- Known active CNS metastases or carcinomatous meningitis.
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
- Has an active infection requiring systemic therapy or uncontrolled infection. Has a known additional malignancy that is progressing or requires active treatment. Has an underlying medical condition that would preclude study participation.
- Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- O2 saturation < 92% (on room air).
- History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden death.
- History or family history of Long QT Syndrome or Torsade de Pointes. Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Class 2 Angina Pectoris or NYHA Heart Failure Class >2. QTcF > 470 msec, PR > 280 msec, Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial treatment.
- Has a known history of HIV (HIV 1/2 antibodies), active / chronic Hepatitis B or C.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03246529
Locations
Show 18 study locations
Sponsors and Collaborators
BioLineRx, Ltd.
Investigators
| Principal Investigator: | John DiPersio, MD | Washington University School of Medicine |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | BioLineRx, Ltd. |
| ClinicalTrials.gov Identifier: | NCT03246529 |
| Other Study ID Numbers: |
BL-8040.SCM.301 |
| First Posted: | August 11, 2017 Key Record Dates |
| Last Update Posted: | June 16, 2022 |
| Last Verified: | June 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders |
Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Lenograstim Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs |